Sue Hughes Intravenous (IV) administration of the antiplatelet agent tirofiban for 72 hours was associated with a reduction in early neurologic deterioration compared with oral aspirin therapy in patients with acute ischemic stroke, in the randomized TREND trial. The results were presented at the International Stroke Conference 2024, held on February 7-9 in Phoenix, Arizona....
Tag: <span>tirofiban</span>
Post
Tirofiban Reduces Early Neurologic Deterioration After Stroke
Intravenous (IV) administration of the antiplatelet agent tirofiban for 72 hours was associated with a reduction in early neurologic deterioration compared with oral aspirin therapy in patients with acute ischemic stroke, in the randomized TREND trial. The results were presented at the International Stroke Conference 2024, held on February 7-9 in Phoenix, Arizona. Lead author...
Post
Higher likelihood of excellent outcome after stroke seen with tirofiban
by Elana Gotkine For patients with stroke of recent onset or progression of stroke symptoms and no occlusion of large or medium-sized cerebral vessels, intravenous tirofiban is associated with an increased likelihood of an excellent outcome, according to a study published online June 1 in the New England Journal of Medicine. Wenjie Zi, M.D., from the...